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Acute natural killer cell pneumonia in a patient
transplanted with autologous haematopoietic stem
cells for systemic sclerosis
SIR, We present here a case of a 31-year-old woman
referred to us for RP with migratory arthralgias, develop-
ment of puffy fingers and subsequent fast, progressive
centripetal skin thickening. Based on the clinical presen-
tation and the presence of anti-topoisomerase-1 antibo-
dies, she was diagnosed with SSc with diffuse cutaneous
involvement reaching a modified Rodnan skin score of 33/
51 despite treatment with low-dose prednisone (5 mg/day)
and oral methotrexate (17.5 mg/week) followed by three
pulses of i.v. cyclophosphamide (15 mg/kg, total dose
3.3 g). Although the high-resolution CT scan of the lung
and a cardiac echo Doppler showed no abnormalities,
the diffusing capacity of the lung for carbon monoxide
(DLCO) was 4.6 mmol/kPa min (54% of the predicted
value) and the bronchoalveolar lavage fluid (BALF) con-
tained many inflammatory cells. We enrolled the patient
in a clinical trial organized by the Autologous Stem cell
Transplantation International Scleroderma group [1] and
she was randomized into the arm of patients receiving
high-dose cyclophosphamide followed by autologous
haematopoietic stem cell transplantation (aHSCT) for
rescue of haematopoiesis. During the first 3 months, the
clinical course was uneventful. She then developed a rap-
idly worsening dyspnoea (upto NYHA class 3), with dry
cough, fever and myalgia under CMV prophylaxis with
valacyclovir 500 mg/b.i.d. Blood gas analysis demon-
strated hypoxaemia and hypercapnia while breathing air.
The HRCT scan of the thorax was consistent with diffuse
ground-glass attenuation. Although the patient never suf-
fered from CMV viraemia, we did detect CMV in BALF
cultures (but no Mycobacterium tuberculosis, Legionella
pneumophila, other Gram-positive or -negative bacteria
or sequels of cytopathic viruses by microscopy). The kin-
etics of CMV-specific antibodies in the patient’s serum
(Fig. 1A) strongly suggested that the exposure to CMV
had occurred not long before the onset of the symptoms.
The BALF contained high numbers of leucocytes
(8.6105 cells/ml) comprising predominantly macro-
phages (40%) and lymphocytes (57%), half of which
FIG. 1 Humoral and cellular immune responses during and after CMV-P.
Anti-CMV antibodies in arbitrary units (A). NK cells (CD3CD56+ lymphocytes), T cells and CD8+ T cells in peripheral
blood (B). Expression of KIR2DL3 on NK cells (C), expression of KIR2DL1 and/or KIR3DL1 on KIR2DL3+ NK cells (D),
expression of NKG2C (E) and K562-induced degranulation (CD107a expression) by single KIR2DL3+ NK cells during
CMV-P (F). FACS data are gated using forward and side scatter gates of viable lymphocytes and gates on either
CD3CD56+ lymphocytes (C) or on CD3CD56+KIR2DL3+ lymphocytes (DF). For further methods and reagents,
see ref. [9]. Pre T: pre-transplant.
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consisted of NK cells. During the first 5 months after pneu-
monitis, (CD56dimCD16+) NK cells were also very abun-
dant in peripheral blood where they outnumbered the
(predominantly CD8+) T cells (Fig. 1B). Most NK cells ex-
pressed the inhibitory KIR2DL3 receptor and were nega-
tive for the other two inhibitory killer inhibitory receptors
(KIRs) (KIR2DL1, KIR3DL1) (Fig. 1C and D). Virtually all
single-KIR2DL3+ cells expressed the activating killer cell
receptor NKG2C (Fig. 1E) associated with anti-CMV re-
sponses [2, 3]. Stimulation with NK cell target cells
(K562) induced a strong NK cell degranulation
(CD107a-expression, Fig. 1F). Hence, the clinical condi-
tion of the patient was associated with the expansion of
highly cytotoxic NKG2C+ NK cells expressing only the
moderately [4] inhibitory KIR2DL3. With time, the patient’s
clinical condition improved and the number of NK cells
normalized. After 2 years, KIR2DL3-single positive repre-
sented no more than 35% of total and displayed consid-
erably less cytotoxicity than at the peak of disease (data
not shown).
aHSCT may be beneficial to patients suffering from
autoimmune diseases such as SSc [1]. CMV-associated
pneumonia (CMV-P) is frequent after lung transplantation
[5] and in patients suffering from graft-vs-host disease
after allogeneic HSCT but less so after aHSCT [6].
It is still under debate whether the pathogenesis of
CMV-P is owed to the cytopathic effect of the virus or to
the immune response it elicits [6, 7]. The fact that severity
of CMV-P is not correlated with the level of viraemia
and treatment with anti-viral drugs does not resolve
its symptoms [6, 7] or that post-transplant CMV-P
occurs mainly during the first 2 months when activated
lymphocytes accumulate in the lungs [7] and that symp-
toms are much more severe when these cells attack pa-
tient’s tissues during graft-vs-host disease argues for the
latter.
However, others stress that T cells are unlikely to be the
harmful component of the pathogenesis of CMV-P be-
cause T-cell recovery after HSCT is slow and CMV-P is
at least as frequent in recipients of T-cell-depleted grafts
[6]. Still, this reasoning may not fully acknowledge the role
of NK cells in pulmonary infections [8]. NK cells recover
very early after transplantation and may recover even
faster in patients with low numbers of T cells [9].
Furthermore, NK cells may represent the major lympho-
cyte population in BALF of patients with CMV-P (reviewed
in [6]). Our patient with CMV-P had high numbers of
NK cells in BALF as well as in peripheral blood that
had expanded just before anti-CMV IgG titres started to
rise. We believe that these only moderately inhibited NK
cells had responded to CMV because the majority was
highly cytotoxic and expressed a single self-specific KIR
in combination with NKG2C, which are all typical features
of NK cells producing IFN-g during acute CMV
reactivation [2, 3].
Our findings support the immunopathological model
and give support to the hypothesis that CMV-P is, at
least in part, caused by hyper-reactive NK cells.
Furthermore, NK cell abnormalities associated with SSc
interstitial lung disease may play a role in these settings
[10]. Our patient may not be an isolated example and may
show that patients receiving aHSCT to cure SSc are at risk
for NK cell-induced CMV-P.
Rheumatology key message
. CMV-P after aHSCT may be caused by NK cells in
patients with SSc interstitial lung disease.
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Remission of juvenile idiopathic arthritis with
primary EpsteinBarr virus infection
SIR, JIA is the most common chronic rheumatic inflamma-
tory disorder in children, and causes acquired disability
and impairment of quality of life [1]. Previous reports
have shown transient or prolonged remission of JIA fol-
lowing viral infections such as measles and varicella
zoster virus [2, 3]. Here we report three cases of JIA
who experienced remission associated with primary EBV
infection. Serum concentrations of cytokines of these pa-
tients suggest that the Th1 response induced by EBV
might have contributed to their remission.
Case 1, a 3-year-old boy, was diagnosed with RF-
negative, ANA-positive oligoarthritis of JIA. He had been
treated with flurbiprofen, MTX 10 mg/m2/week and predni-
solone (PSL) 0.2 mg/kg/day, but he continued to have
mildly active arthritis. Ten months after presentation,
he developed fever and tonsillitis. Laboratory studies re-
vealed a white blood count (WBC) of 7840/ml with 8%
atypical lymphocytes, and EBV infection was serologically
confirmed. With the development of infectious mono-
nucleosis (IM), MTX was discontinued. Symptoms of IM
were mild, and he recovered from fever in several days.
His left knee joint swelling diminished within several
weeks after the onset of IM. During the 2 years of
follow-up, he has remained in remission despite with-
drawal of MTX and PSL (Fig. 1).
Case 2, a 1-year-old girl, was diagnosed with
RF-negative polyarthritis of JIA. She had been treated
with flurbiprofen, PSL 0.2 mg/kg/day and MTX 10 mg/
m2/week. Arthritis improved with treatment, but recurrent
episodes of active arthritis associated with tapering of
PSL were observed. At 8 years of age, she developed
low-grade fever and tonsillitis. Laboratory studies
revealed WBC of 15 800/ml with 4% atypical lymphocytes,
and EBV infection was serologically confirmed. High EBV
load (>5000 copies/ml) remained detectable until
17 months after EBV infection. MTX was discontinued
with the development of IM, but her joint swelling dimin-
ished within 3 months after the onset of IM. During the
18 months of follow-up, she has remained in remission
(Fig. 1).
Case 3, a 3-year-old girl, was diagnosed with RF-
negative, ANA-positive oligoarthritis of JIA. She had
been treated with flurbiprofen, MTX 8 mg/m2/week and
PSL 0.3 mg/kg/day, but she continued to have mildly
active arthritis for 3 years. At 7 years of age, lymphaden-
opathy and elevation of aminotransferase levels were
discovered during a routine hospital visit. Laboratory
studies revealed WBC of 5790/ml without atypical lympho-
cytes and aspartate aminotransferase of 114 IU/l. EBV
infection was serologically confirmed. MTX was discontin-
ued, but her arthritis improved gradually and diminished
within 3 months after the onset of EBV infection. She
has remained in remission during 3 years of follow-up
(Fig. 1).
The serum concentrations of IFN-g, IL-1b, IL-6, IL-17
and IL-23 were examined by ELISA. In all three patients,
concentrations of IFN-g were elevated in accordance
with the onset of IM. In patients 1 and 2, concentrations
of IL-17 decreased around the onset of IM and remained
in the normal range thereafter. In patient 3, concentrations
of IL-17 were not elevated at 2 months prior to EBV infec-
tion, but cytokines could not be measured at further
time points because serum samples were not available
(Fig. 1). IL-1b, IL-6 and IL-23 were not elevated in any
serum samples.
Because MTX is widely used for treatment of JIA, it
would not be rare for JIA patients receiving MTX to de-
velop primary EBV infection. In our cases, MTX was dis-
continued when EBV infection was suspected because
MTX might aggravate the EBV infection via its immuno-
suppressive effects [4]. Although these patients had been
refractory to MTX, and had mildly active arthritis at the
onset of EBV infection, they did not show exacerbation
of articular symptoms and attained remission without
MTX. Concentrations of MMP-3, which is a useful
marker of disease activity in JIA, decreased to normal
range at onset of EBV infection or within several months
in all patients [5].
It has been previously hypothesized that auto-
inflammatory arthritis is associated with a Th1 polarized
response at the site of inflammation. However, Th17 cells
with pro-inflammatory actions are thought to be critical to
the pathogenesis of CIA, as demonstrated in a murine
model [6]. Recent evidence suggests that Th17 cells,
rather than Th1 cells, may be central to disease pathogen-
esis of RA and JIA [7]. Differentiation and stabilization of
Th17 cells depends on a range of cytokines, including IL-6
and IL-23. On the other hand, IFN-g produced by Th1 cells
inhibits the Th17 pathway [6]. It is possible that the
Th1 response induced by EBV infection contributed to
the remission of JIA, because primary EBV infection
strongly induces IFN-g production of CD8+ T cells [8].
Understanding the immunological effect of remission
of JIA with viral infections may provide insights into de-
signing more effective therapies for JIA.
Rheumatology key message
. JIA patients who were refractory to MTX treat-
ment showed remission after primary EBV infection.
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